FineGene Biotech

Though small, the company contributes to CSR, supporting screening project of hearing loss

Though FineGene is a start-up company, it fully understands its responsibilities and is willing to take part in the role of contributing and caring for people, society and our planet.

As FineGene growing further in the biotech market, it notices that there is a group of people suffer from hearing loss or even are considered "deaf". These "hard to hear" symptoms are caused by many factors or even inherit from families. And based on researches, most of the hearing loss can be treated or not becoming deteriorate if taking early intervention or treated at the early stage.

In order to help those people who are with high risk of hearing loss caused by gene mutation, FineGene sponsors and participates a cooperation with Children's Hospital of Fudan University. The two parties will work together inventing a rapid detecting system that can determines whether people bring the gene hotspots such as GJB2, mtDNAA1555G, and SLC26A4 , corresponding with hearing loss.

And through the partnership of hospitals and social resources (companies), it will provide reliable finance supports, save costs and time, improve the processing management and strengthen research ability. During the cooperation, new innovations and inventions on sample processing, epidemic research will also bring new patents and establish data base system.

FineGene Biotech and Children's Hospital signed the agreement of cooperation. The project has already started in this early March, 2019. Next, FineGene will provide innovated samples collection tools and genomic DNA purification reagent kits.